Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Bio-Rad, GenTel, NIH

Premium

Ciphergen to Sell Proteomics Tools Arm to Bio-Rad as Q2 Revenues Fall 24 Percent
 
Bio-Rad this week said it plans to acquire Ciphergen’s proteomic business for $20 million and buy a $ 3-million stake in the company [See related story].
 
Ciphergen announced the sale as it reported that second-quarter revenues dropped 24 percent to $5.3 million from $6.9 million during the year-ago period.
 
Net losses for the quarter ended June 30 declined 18 percent to $7.7 million from $9.4 million during the year-ago period.
 
As of June 30, the company had $20.6 million in cash and cash equivalents. The company spent $2.9 million in research in development during the quarter.
 

 
GenTel Allowed to Commercialize Protein Glycosylation Technology
 
The Van Andel Research Institute has allowed GenTel BioSciences to commercialize a microarray technology for measuring variations in the glycosylation of proteins, the companies announced this week.
 
The technology uses antibody microarrays to profile changes in the glycosylation of proteins and could lead to the discovery of disease-specific alterations in protein glycosylation and new biomarker diagnostics, said Brian Haab of VARI and the inventor of the technology.
 
Financial terms of the deal were not disclosed.
 

 
$21.5M in NIH Grants for Proteomics and Genomics
 
The National Institutes of Health has set aside $21.5 million for 14 grants to help a number of academic labs buy high-end instruments, including mass spectrometers, sequencers, and supercomputers, the agency said this week.
  • The University of Washington received $500,000 for a multi-tiered proteomic compute cluster for protein chemistry studies to study lung injury diseases, toxicity, and drug-induced liver disease;
  • The University of California at Santa Barbara and the University of Virginia each received $2 million for an 800-megahertz nuclear magnetic resonance spectrometer. UCSB will study protein interactions with bacteria, and UVA will focus on biopolymers and membrane proteins; 
  • The University of California at Los Angeles received $1.2 million for a high-resolution, hybrid Fourier transform ion cyclotron resonance mass spectrometer to study neurodegenerative diseases, respiratory illnesses, and cancer;
  • The University of Maryland in Baltimore County received $1.5 million for a hybrid, 12 Tesla quadrupole/trap-Fourier transform ion cyclotron resonance mass spectrometer to characterize nucleic acids; and
  • Stanford University received $543,750 for an ultra-high-throughput genome sequencing system that performs clonal amplification and pyrosequencing to support microbial genome sequencing.
The one-time awards fund a maximum of $2 million to research institutions purchasing sophisticated instruments as part of biomedical research. The awards will be made through The National Center for Research Resources.
 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.